ICON is a Global Contract Research Organisation (CRO). We specialise in the strategic development, management and analysis of programs that support Clinical Development; from compound selection to Phase I-IV clinical studies.
Our services can be implemented separately or as part of a comprehensive full service clinical programme that can help expedite the time it takes to bring a drug to market and monitor its performance and safety post approval.
Share Price NASDAQ
Data Provided by Refinitiv. Minimum 15 minutes delayed.